Prognostic Factors in Stage i Lung Cancer;Cáncer de pulmón en estadio i y factores pronósticos

Archivos de Bronconeumologia

Volumn 51, Issue 9, 2015, Pages 427-428

  Sánchez de Cos Escuín, Julio ^a,b  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PROGNOSIS; CANCER STAGING; EDITORIAL; LUNG CANCER; HUMAN; LUNG NEOPLASMS; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER RECURRENCE; GENE MUTATION; METASTASIS POTENTIAL; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; SECOND CANCER; SURGICAL MARGIN; TUMOR DIFFERENTIATION; TUMOR INVASION;

HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84940451192     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2015.06.015     Document Type: Article

References (10)

1. Allemani C., Weir H.K., Carreira H., Harewood R., Spika D., Wang X.-S., et al. Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015, 385:977-1010. CONCORD Working Group.
2. Hollander N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. (Eds.), SEER Cancer Statistics Review 1975-2011. National Cancer Institute. Bethesda MD [consultado Feb 2015]. Disponible en: http://seer.cancer.gov/csr/1975-2011.
3. Rami-Porta R., Ball D., Crowley J., Giroux D.J., Jett J., Travis W.D., et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007, 2:593-66012. International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions.
4. Naito Y., Goto K., Nagai K., Ishii G., Nishimura M., Yoshida J., et al. Vascular invasion is a strong prognostic factor after complete resection of node-negative non-small cell lung cancer. Chest 2010, 138:1411-1417.
5. Maeda R., Yoshisa J., Ishii G., Hishida T., Nishimura M., Nagai K. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer. Patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification. Chest 2011, 140:1494-1502.
6. Kratz R., He J., van Den Eeden S.K., Zhu Z.-H., Gao W., Pham P.T., et al. A practical molecular assay to predict survival in resected nonsquamous non-small-cell lung cancer: Development and international validation studies. Lancet 2012, 379:823-832.
7. Subramanian J., Simon R. Gene-expression-based prognostic signatures in lung cancer: Ready for clinical use?. J Natl Cancer Inst 2010, 102:464-474.
8. NCCN Clinical practice guidelines in Oncology. Non-small cell lung cancer National Cancer Comprehensive Network 2011. [consultado 18 Dic 2014]. Disponible en: http://www.nccn.org/professionals/physicia_gls/PDF/nslc.pdf.
9. Peñalver J.C., Jordá C., Mancheño N., Cerón J.A., de Aguiar K., Arrarás M., et al. Factores pronóstico en el carcinoma bronquial no microcítico menor de 3 centímetros (análisis actuarial, incidencia acumulativa y grupos de riesgo). Arch Bronconeumol 2015, 51:431-439.
10. Andrade S., D'Cunha J., Maddaus A., Groth S.S., Rueth N.M., Hodges J.S., et al. Conditional cancer-specific versus cardiovascular-specific survival after lobectomy for stage I non-small cell lung cancer. Ann Thorac Surg 2010, 90:375-382.